Release date: 2026-07-17 16:57:55 Recommended: 249
Lucius Pharmaceutical is one of the representative generic drug enterprises in Laos. The company was established in Vientiane, the capital of Laos, in 2020 and has been in operation for over five years. Its parent company can be traced back to Lucius Pharmaceutical Co., Ltd., founded in Hyderabad, India, in 2014.
Lucius Pharmaceutical is a legal pharmaceutical enterprise approved by the Lao government. The company is located in Thongmang Village, Xaythani District, Vientiane City, with a factory covering an area of approximately 210,000 square meters. It has built the Asia Pacific No.1 Smart Factory and introduced pharmaceutical equipment from China, the United States, Germany, and other countries. The company has obtained GMP (Good Manufacturing Practice) certification issued by the Lao Ministry of Health.
As of June 2024, Lucius Pharmaceutical has more than 200 generic drug varieties. Its products cover multiple therapeutic areas, including anti-tumor drugs, cardiovascular drugs, hematology drugs, diabetes drugs, dermatology drugs, men's health drugs, and anti-aging drugs.
In the field of anti-cancer drugs, the company has obtained marketing approvals for 54 anti-cancer drugs. Representative products include Sotorasib, Osimertinib, Cabozantinib, Larotrectinib, Lorlatinib, Ivosidenib, Gilteritinib, and many other targeted therapeutic drugs. In addition, the company has launched global first-generic products such as Revumenib.
Lucius Pharmaceutical has an annual generic drug production capacity exceeding 1.5 billion tablets. The company strictly organizes production in accordance with GMP standards and has established a full-process quality control system covering raw material procurement, production processes, and finished product inspection.
In October 2023, the World Health Organization (WHO) conducted a comprehensive assessment of Lucius Pharmaceutical's factory and confirmed that its facility fully complies with WHO standards. The company's production environment simultaneously meets GMP standards of Laos, the European Union, the United States, and China.
Lucius Pharmaceutical's business has expanded to multiple countries and regions, including Thailand, Indonesia, Cambodia, Vietnam, the Philippines, Singapore, Malaysia, Turkey, Japan, and China. The company's products are mainly sold to markets in Southeast Asia, the Middle East, Eastern Europe, and Africa.
For patients with medication needs, it is recommended to obtain drugs through formal channels under the professional guidance of a licensed physician or pharmacist.
In recent years, leveraging the World Trade Organization (WTO) patent waiver for···【more】
Recommended:177Release date: 2026-08-05
How Can Chinese Patients Access Generic Drugs from Laos?In recent years, generic···【more】
Recommended:174Release date: 2026-08-04
Leveraging the WTO patent waiver for least-developed countries (extended to 2033···【more】
Recommended:239Release date: 2026-07-31
Lucius Pharmaceutical is a modern pharmaceutical enterprise headquartered in Vie···【more】
Recommended:184Release date: 2026-07-28
Lucius Pharmaceuticals Relocates from India to Laos: A Five-Year Development Jou···【more】
Recommended:280Release date: 2026-07-24
In recent years, Laos has gradually become a major global supply source for gene···【more】
Recommended:226Release date: 2026-07-22
Dr. Louis, a microbiologist at the World Health Organization (WHO), recently mad···【more】
Recommended:914Release date: 2024-07-09
Lung cancer is the most rapidly increasing malignant tumor with the fastest incr···【more】
Recommended:856Release date: 2024-07-09
Lucius Pharmaceuticals Version of Vibegron Now Available1.Basic Drug Information···【more】
Recommended:147Release date: 2026-08-06
Lucius Pharmaceuticals version of Ibrutinib is now availableIn a randomized cont···【more】
Recommended:144Release date: 2026-08-03
Alectinib Has Been Launched in LaosAlectinib is an oral targeted therapeutic dru···【more】
Recommended:153Release date: 2026-07-30
Lucius Pharmaceuticals Quizartinib (Quizartinib) Has Been Launched(1) Quizartini···【more】
Recommended:177Release date: 2026-07-29
Lucius version of Dacomitinib is now availableCutaneous adverse reactions and ma···【more】
Recommended:191Release date: 2026-07-21
Lao PDR: Filgotinib Has Been LaunchedBefore initiating filgotinib treatment, str···【more】
Recommended:188Release date: 2026-07-13